The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

China’s NMPA has approved MSD’s WELIREG (belzutifan) to treat adult individuals with certain types of VHL disease-associated ...

Since 2023, the pharmaceutical industry operating in Europe has faced an unprecedented challenge related to drug shortages.

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma ’s Attruby (acoramidis), an oral transthyretin (TTR) ...

Novo Nordisk and Ypsomed’s 2023 deal is rumoured to include an autoinjector supply for potential Wegovy successor CagriSema.

Novartis has announced the acquisition of Kate Therapeutics to enhance its portfolio of gene therapies for inherited ...

Kura has partnered Kyowa Kirin in a strategic global collaboration for developing and commercialising oral ziftomenib to ...

Diagnosed prevalent cases of Parkinson’s disease will grow at 1.94% annually in the seven major markets between 2023 and 2033 ...

Johnson & Johnson Innovation Medicine has submitted a request to the FDA to approve Tremfya as a treatment for ulcerative ...

Zai Lab and Pfizer have entered a strategic collaboration for the commercialisation of XACDURO in mainland China.

The companies have teamed up to develop Takeda’s proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell ...

Health Canada has issued a Notice of Compliance (NOC) for Johnson & Johnson’s (J&J) CARVYKTI for multiple myeloma treatment.